VanEck announced today its distributions per share for its VanEck Vectors® exchange-traded funds. The following dates apply to...
VanEck announced today its regular distribution per share for the following VanEck Vectors® equity exchange-traded fund. ...
ESPO provides targeted exposure to “the future of sports”: video game and related software developers, streaming services, companies involved...
VanEck announced today its regular distributions per share for the VanEck Vectors® equity exchange-traded funds. ...
VanEck announced today its regular distributions per share for its VanEck Vectors® equity exchange-traded funds. Ex-Date ...
- Treatment in Combination with Radiation Doubled Survival Time and Produced Long-Term Cures in Lethal Brain Cancer Model - - Confirms...
--Broad New Patent Covers Peregrine's Lead PS-Targeting Antibody Bavituximab and Similar Agents for the Treatment of All Viral Infections-- --New...
TUSTIN, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHMD) today announced that on November 3, 2009, the...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT...
FORM 4 [ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
- 28 of 46 (61%) Patients Receiving Bavituximab in Combination with Docetaxel Achieved Objective Tumor Response by End of Planned Treatment Cycles...
- During a 24-Year Career at Genentech, Dr. Garnick was Responsible for the Approval of 17 Products Including Rituxan(R), Herceptin(R), Avastin(R...
TUSTIN, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) today announced that the previously announced...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.